The present invention provides an LFA-1 inhibitor comprising at least one member selected from the group consisting of polyamines represented by general formula (1) and pharmaceutical acceptable salts thereof: NH.sub.2--(CH.sub.2)m1-(NH)p1-(CH.sub.2)m2-(NH)p2-(CH.sub.2)m3-(NH)p3-(CH- .sub.2)m4-(NH)p4-(CH.sub.2)m5-NH.sub.2 (1), wherein at least two of m1 to m5 exceed 0, each of m1 to m5 is independently an integer of 0 to 7, the sum of m1+m2+m3+m4+m5 is 2 or more but less than 18, at least one of p1, p2, p3 and p4 is 1, and each of others independently represents 0 or 1. The present invention also provides a pharmaceutical composition containing the LFA-1 inhibitor and a method for the inhibition or the treatment of diseases.